Media Room

Fourth quarter and full year 2023 results

Fourth quarter and full year 2023 results were reviewed by management during a live audio webcast with the financial community on February 1st, 2024. The presentation was followed by a Q&A session.

Press releases

February 24, 2024
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
February 24, 2024
Media Update: Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma
February 23, 2024
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Contact our media team

You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.

For any other request, please call the switchboard: +33 1 53 77 40 00


Half Year 2023 Financial Report
Download PDF
Half Year 2023 Financial Report XBRL Package
Download PDF
First quarter 2023 results
Download PDF
XBRL package 20F 2023
Download PDF

Email Alerts

Subscribe to our email alerts to receive our press releases.